OnCo
ideasIdea

Predict immune side-effects before they happen and pre-empt them

Immunotherapy can trigger dangerous attacks on the gut, lungs or heart. Use blood, gut bacteria and genetic markers to spot who is at risk and act early.

Immune-related adverse events cause treatment discontinuation and death, and their management is reactive. Autoantibody profiles, HLA types, microbiome composition, baseline cytokines and early T-cell clonal expansion are each associated with specific toxicities in retrospective series. The proposal is a prospective biomarker cohort across checkpoint inhibitor indications to derive and validate a toxicity risk model, followed by trials of pre-emptive strategies (early steroid-sparing agents, microbiome modulation, intensified monitoring) in high-risk patients.

Hypothesis
A validated model identifies a high-risk group with at least threefold risk of grade 3+ immune toxicity, and pre-emptive management reduces severe events and discontinuations without reducing response rates.
Rationale
Toxicity and efficacy are partially separable; preventive strategies such as prophylactic vedolizumab or IL-6 blockade have early data suggesting response is preserved.
What would test it
Prospective 3,000-patient cohort with banked samples; then a randomised trial of pre-emptive management in model-defined high-risk patients.
Maturity
preclinical evidence
Who has to act
research
Cost to try
Medium ($1M to $50M)
Years to first evidence
4
Bottlenecks it attacks

Connected

6top

Pages like this

not linked directly; found by shared links